Diagnostic value and risk correlation of serum heart-type fatty acid-binding protein (H-FABP) and osteoprotegerin (OPG) in chronic heart failure
Abstract
Objective: To analyze the value of H-FABP and OPG in determining severity of heart function in those suffering from long-term heart failure.
Method: 196 patients with persistent heart failure who were admitted to our hospital between June 2023 and October 2024 were chosen. A comparison was made between the three groups of chronic heart failure patients' general clinical information, H-FABP, and OPG levels. The associations between OPG and H-FABP and various clinical forms of chronic heart failure, heart failure severity, and measurement markers related to echocardiography were examined. To assess NT-proBNP, H-FABP, and OPG detection alone and in combination for HFrEF and HFpEF in order to determine their diagnostic utility. Following their discharge, all patients were monitored for three to six months.
Results: There was a positive correlation (r=0.61) between H-FABP and the NYHA classification, LA (r=0.46), LV (r=0.51), HS-TnT (r=0.31), NT-proBNP (r=0.58), SUA (r=0.38), etc., and negatively correlated with the LVEF (r=-0.76), NT-proBNP (r=0.49), etc., and negatively correlated with the LVEF (r=-0.60) (P<0.05). Binary logistic regression analysis of NT-proBNP, H-FABP, and OPG levels and endpoint events revealed that NT-proBNP had a high value in predicting endpoint events. The readmission rate and mortality rate of patients with chronic heart failure increased with increasing NT-proBNP concentration. Serum H-FABP and OPG all have high diagnostic value for HFrEF. Compared with the traditional biomarker NT-proBNP, H-FABP had a greater sensitivity (94.9%) and specificity (83.1%) in the diagnosis of HFrEF, whereas OPG had a greater sensitivity (92.3%) and a lower specificity (57.7%). H-FABP and OPG can significantly improve the sensitivity (86.44%) and specificity (89.74%) in the diagnosis of patients with HFrEF. Serum NT-proBNP, H-FABP and OPG all have high diagnostic value for HFpEF. Compared with the traditional biomarker NT-proBNP, H-FABP has greater sensitivity (91.7%) and specificity (82.0) in the diagnosis of HFpEF, whereas OPG has greater specificity (82.0%) and lower sensitivity (58.3%).
Conclusion: The combined detection of H-FABP, OPG and NT-proBNP can be used as an important strategy for the early detection of heart failure patients' declining cardiac function.
References
2.Teramoto K, Tay WT, Tromp J, Ouwerkerk W, Teng TK, Chandramouli C, Liew OW, Chong J, Poppe KK, Lund M, Devlin G, Troughton RW, Doughty RN, Richards AM, Lam CSP. Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure. J Am Heart Assoc. 2024 May 7;13(9):e032254. doi: 10.1161/JAHA.123.032254. Epub 2024 Apr 19. PMID: 38639333; PMCID: PMC11179931.
3.Bayés-Genis A, Taylor CJ. Elevated NT-proBNP in Heart Failure and CKD: A Genuine Red Flag for Worse Prognosis-Not a False Positive. JACC Heart Fail. 2025 Jan;13(1):40-42. doi: 10.1016/j.jchf.2024.10.012. PMID: 39779182.
4.Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, Chioncel O, Defilippi CR, Drazner MH, Felker GM, Filippatos G, Fiuzat M, Ide T, Januzzi JL Jr, Kinugawa K, Kuwahara K, Matsue Y, Mentz RJ, Metra M, Pandey A, Rosano G, Saito Y, Sakata Y, Sato N, Seferovic PM, Teerlink J, Yamamoto K, Yoshimura M. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. J Card Fail. 2023 May;29(5):787-804. doi: 10.1016/j.cardfail.2023.02.009. Epub 2023 Apr 17. PMID: 37117140.
5.Nougué H, Michel T, Picard F, Lassus J, Sadoune M, Laribi S, Cohen-Solal A, Logeart D, Launay JM, Vodovar N. Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment. Clin Chem. 2023 Apr 3;69(4):350-362. doi: 10.1093/clinchem/hvac225. PMID: 36762414.
6.Walter E, Arrigo M, Allerstorfer S, Marty P, Hülsmann M. Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland. J Med Econ. 2023 Jan-Dec;26(1):1287-1300. doi: 10.1080/13696998.2023.2264722. Epub 2023 Oct 18. PMID: 37781889.
7.Pastore MC, Mandoli GE, Stefanini A, Ghionzoli N, Carrucola C, De Carli G, Lisi M, Cavigli L, D'Ascenzi F, Focardi M, Valente S, Patti G, Mondillo S, Cameli M. Prediction of congestive state in acute and chronic heart failure: The association between NT-proBNP and left atrial strain and its prognostic value. Int J Cardiol. 2023 Jan 15;371:266-272. doi: 10.1016/j.ijcard.2022.08.056. Epub 2022 Sep 5. PMID: 36067924.
8.Núñez-Marín G, Palau P, Domínguez E, de la Espriella R, López L, Flor C, Marín P, Lorenzo M, Miñana G, Bodí V, Sanchis J, Núñez J. CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction. Clin Kidney J. 2024 Jul 2;17(8):sfae199. doi: 10.1093/ckj/sfae199. Erratum in: Clin Kidney J. 2024 Nov 20;17(11):sfae344. doi: 10.1093/ckj/sfae344. PMID: 39135938; PMCID: PMC11317843.
9.Su X, Lei T, Yu H, Zhang L, Feng Z, Shuai T, Guo H, Liu J. NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2023 May 10;18:811-825. doi: 10.2147/COPD.S396663. PMID: 37197601; PMCID: PMC10183357.
10.Landolfo M, Spannella F, Giulietti F, Ortensi B, Stella L, Carlucci MA, Galeazzi R, Turchi F, Luconi MP, Zampa R, Cecchi S, Tortato E, Petrelli M, Sarzani R. Detecting heart stress using NT-proBNP in patients with type 2 diabetes mellitus and hypertension or high-normal blood pressure: a cross-sectional multicentric study. Cardiovasc Diabetol. 2024 Aug 12;23(1):297. doi: 10.1186/s12933-024-02391-z. PMID: 39135091; PMCID: PMC11321074.
11.Rammos A, Bechlioulis A, Kalogeras P, Watson CJ, Salvo P, Lomonaco T, Kardakari O, Tripoliti EE, Goletsis Y, Fotiadis DI, Katsouras CS, Michalis LK, Naka KK. The Potential Role of Salivary NT-proBNP in Heart Failure. Life (Basel). 2023 Aug 28;13(9):1818. doi: 10.3390/life13091818. PMID: 37763222; PMCID: PMC10532738.
12.Yang Z, Ma H, Yin D, Sun C. Impact of Sacubitril/Valsartan on Cardiac Structure and Blood Levels of miRNA-328 and NT-proBNP in Patients with CHD and Chronic Heart Failure. Altern Ther Health Med. 2024 Jun 21:AT10778. Epub ahead of print. PMID: 38904619.
13.Osser G, Osser B, Toth C, Miuța CC, Marconi GR, Bondar LI. Exploring the Relationship Between Ejection Fraction, Arterial Stiffness, NT-proBNP, and Hospitalization Risk in Heart Failure Patients. Diagnostics (Basel). 2024 Dec 22;14(24):2885. doi: 10.3390/diagnostics14242885. PMID: 39767246; PMCID: PMC11675150.
14.Sakamoto D, Sotomi Y, Matsuoka Y, Nakatani D, Okada K, Sunaga A, Kida H, Sato T, Kitamura T, Seo M, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Tamaki S, Yasumura Y, Yamada T, Hikoso S, Sakata Y; OCVC-Heart Failure Investigators. Prognostic Utility and Cutoff Differences in NT-proBNP Levels Across Subgroups in Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-HFpEF Registry. J Card Fail. 2025 May;31(5):771-780. doi: 10.1016/j.cardfail.2024.10.440. Epub 2024 Nov 16. PMID: 39557334.
15.Kondo T, Campbell R, Jhund PS, Anand IS, Carson PE, Lam CSP, Shah SJ, Vaduganathan M, Zannad F, Zile MR, Solomon SD, McMurray JJV. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2024 Aug;12(8):1442-1455. doi: 10.1016/j.jchf.2024.04.027. Epub 2024 Jun 19. PMID: 38904646.
16.Iosifov AV, Shtegman OA. Utility of Point-of-Care Diagnosis of Chronic Heart Failure Using an Express Test for Semi-Quantitative Determination of NT-proBNP Levels. Kardiologiia. 2024 Jul 31;64(7):27-30. Russian, English. doi: 10.18087/cardio.2024.7.n2647. PMID: 39102570.
17.Sharma S, Mathur D, Goswami S, Gupta MK, Bhardwaj P, Kumar P, Deora S. Prevalence of periodontitis in chronic heart failure patients and its relationship with NT-ProBNP: A cross-sectional study. Indian Heart J. 2025 Mar-Apr;77(2):110-113. doi: 10.1016/j.ihj.2025.03.004. Epub 2025 Mar 7. PMID: 40057232; PMCID: PMC12138112.
18.Millogo GRC, Thiam Tall A, Seghda TAA, Kambiré Y, Nongkouni E, Dabiré YE, Kagambéga LJ, Kologo JK, Yaméogo VN, Marcaggi X, Zabsonré P. Contribution du test de marche de six minutes et des taux de NT-proBNP à l'admission et la sortie dans l’évaluation pronostique de l'insuffisance cardiaque classe II-III de la NYHA [Contribution of the 6-minutes walking test and the plasma NT-proBNP at admission and discharge to the prognostic evaluation of patients with NYHA class II-III Heart Failure.]. Ann Cardiol Angeiol (Paris). 2023 Nov;72(5):101639. French. doi: 10.1016/j.ancard.2023.101639. Epub 2023 Sep 15. PMID: 37717311.
19.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
20.Dutta A, Mooventhan A, Nivethitha L. Yoga as Adjunct Therapy for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Avicenna J Med. 2023 Sep 22;13(3):151-162. doi: 10.1055/s-0043-1774738. PMID: 37799183; PMCID: PMC10550367.
21.Sezai A, Abe M, Maruyama T, Taoka M, Sekino H, Tanaka M. A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment. J Clin Med. 2024 May 8;13(10):2764. doi: 10.3390/jcm13102764. PMID: 38792306; PMCID: PMC11122572.
22.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
23.He X, Jiang Y, Li S, Liu D, Li Z, Han X, Zhang X, Dong X, Liu H, Huang J, Wang X, Long W, Ni S, Yang Z, Ye T. Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Coronary Heart Disease Complicating Chronic Heart Failure (Syndrome of Qi Deficiency with Blood Stasis): Study Protocol for a Randomized, Placebo-Controlled, Double-Blind and Multi-Centre Phase II Clinical Trial. Int J Gen Med. 2023 Dec 28;16:6177-6188. doi: 10.2147/IJGM.S436999. PMID: 38169574; PMCID: PMC10758342.
24.Yan Q, Chen X, Yu C, Yin Y. Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024 Nov 22;24(1):663. doi: 10.1186/s12872-024-04316-w. PMID: 39578752; PMCID: PMC11583546.
25.Göpfert D, Traub J, Sell R, Homola GA, Vogt M, Pham M, Frantz S, Störk S, Stoll G, Frey A. Profiles of cognitive impairment in chronic heart failure-A cluster analytic approach. Front Hum Neurosci. 2023 Apr 20;17:1126553. doi: 10.3389/fnhum.2023.1126553. PMID: 37151899; PMCID: PMC10157093.
26.Yan L, Ai Y, Xing Y, Wang B, Gao A, Xu Q, Li H, Chen K, Zhang J. Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis. Front Cardiovasc Med. 2023 Feb 1;10:1107672. doi: 10.3389/fcvm.2023.1107672. PMID: 36818339; PMCID: PMC9933506.
27.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
28.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
29.Ivey-Miranda JB, Almeida-Gutierrez E, Herrera-Saucedo R, Posada-Martinez EL, Chavez-Mendoza A, Mendoza-Zavala GH, Cigarroa-Lopez JA, Magaña-Serrano JA, Rivera-Leaños R, Treviño-Mejia A, Revilla-Matute C, Flores-Umanzor EJ, Espinola-Zavaleta N, Orea-Tejeda A, Garduño-Espinosa J, Saturno-Chiu G, Rao VS, Testani JM, Borrayo-Sanchez G. Sodium restriction in patients with chronic heart failure and reduced ejection fraction: A randomized controlled trial. Cardiol J. 2023;30(3):411-421. doi: 10.5603/CJ.a2021.0098. Epub 2021 Sep 7. PMID: 34490604; PMCID: PMC10287066.
30.Traub J, Schuhmann MK, Sell R, Frantz S, Störk S, Stoll G, Frey A. S100B Serum Levels in Chronic Heart Failure Patients: A Multifaceted Biomarker Linking Cardiac and Cognitive Dysfunction. Int J Mol Sci. 2024 Aug 22;25(16):9094. doi: 10.3390/ijms25169094. PMID: 39201780; PMCID: PMC11354705.
31.Fuery MA, Leifer ES, Samsky MD, Sen S, O'Connor CM, Fiuzat M, Ezekowitz J, Piña I, Whellan D, Mark D, Felker GM, Desai NR, Januzzi JL, Ahmad T. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2024 Mar;12(3):479-487. doi: 10.1016/j.jchf.2023.11.007. Epub 2023 Dec 20. PMID: 38127049.
32.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
Copyright (c) 2025 Weifeng Zheng, Mingda Liu, Sanduo Xu, Wang Xu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.